Saltar al contenido

Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026

30 de septiembre de 2026 · 9 min

Notas del episodio

Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.

In this episode
  1. Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page

    Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page # Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme Swapnadip Roy and Vicky Ramancha were indicted on smuggling and conspiracy charges for distributing counterfeit Ozempic, with Roy appearing in a Florida federal court following his extradition from Italy. via CBS…

  2. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz

    Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes # Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes By PR Newswire | September 29, 2026, 6:00 PM In…

  3. Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma

    Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan # Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan By Fraiser Kansteiner Sep 29, 2026 11:20am Finding unique features to pin one’s GLP-1 pitch on has become increasingly important both for developers hoping to catch the next wave of obesity treatments and for Novo’s and Lilly’s…

  4. Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!

    Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! News Release 28-Sep-2026 # Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway New research to be presented at the Annual Meeting of…

  5. Step Back — With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?Background sources

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Todos los episodios de GLP-1 Daily: Ozempic & Wegovy News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.